Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients

被引:17
作者
Huygens, Simone A. [1 ,2 ,3 ]
Ramos, Isaac Corro [3 ]
Bouten, Carlijn V. C. [4 ]
Kluin, Jolanda [5 ]
Chiu, Shih Ting [6 ]
Grunkemeier, Gary L. [6 ]
Takkenberg, Johanna J. M. [1 ]
Rutten-van Molken, Maureen P. M. H. [2 ,3 ]
机构
[1] Erasmus MC, Dept Cardiothorac Surg, Univ Med Ctr, Rotterdam, Netherlands
[2] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Rotterdam, Netherlands
[3] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands
[4] Eindhoven Univ Technol, Dept Biomed Engn, Eindhoven, Netherlands
[5] Acad Med Ctr, Dept Cardiothorac Surg, Amsterdam, Netherlands
[6] Providence Hlth & Serv, Med Data Res Ctr, Portland, OR USA
关键词
Early health technology assessment; Patient-level simulation model; Heart valve implantation; Tissue-engineered heart valves; QUALITY-OF-LIFE; MYOCARDIAL-INFARCTION; NEPRILYSIN INHIBITION; ECONOMIC-EVALUATION; CASE-FATALITY; TRANSCATHETER; REPLACEMENT; RISK; MORTALITY; SURVIVAL;
D O I
10.1007/s10198-020-01159-y
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives Aortic valve disease is the most frequent indication for heart valve replacement with the highest prevalence in elderly. Tissue-engineered heart valves (TEHV) are foreseen to have important advantages over currently used bioprosthetic heart valve substitutes, most importantly reducing valve degeneration with subsequent reduction of re-intervention. We performed early Health Technology Assessment of hypothetical TEHV in elderly patients (>= 70 years) requiring surgical (SAVR) or transcatheter aortic valve implantation (TAVI) to assess the potential of TEHV and to inform future development decisions. Methods Using a patient-level simulation model, the potential cost-effectiveness of TEHV compared with bioprostheses was predicted from a societal perspective. Anticipated, but currently hypothetical improvements in performance of TEHV, divided in durability, thrombogenicity, and infection resistance, were explored in scenario analyses to estimate quality-adjusted life-year (QALY) gain, cost reduction, headroom, and budget impact. Results Durability of TEHV had the highest impact on QALY gain and costs, followed by infection resistance. Improved TEHV performance (- 50% prosthetic valve-related events) resulted in lifetime QALY gains of 0.131 and 0.043, lifetime cost reductions of euro639 and euro368, translating to headrooms of euro3255 and euro2498 per hypothetical TEHV compared to SAVR and TAVI, respectively. National savings in the first decade after implementation varied between euro2.8 and euro11.2 million (SAVR) and euro3.2-euro12.8 million (TAVI) for TEHV substitution rates of 25-100%. Conclusions Despite the relatively short life expectancy of elderly patients undergoing SAVR/TAVI, hypothetical TEHV are predicted to be cost-effective compared to bioprostheses, commercially viable and result in national cost savings when biomedical engineers succeed in realising improved durability and/or infection resistance of TEHV.
引用
收藏
页码:557 / 572
页数:16
相关论文
共 68 条
[1]   Guidelines for reporting mortality and morbidity after cardiac valve interventions [J].
Akins, Cary W. ;
Miller, D. Craig ;
Turina, Marko I. ;
Kouchoukos, Nicholas T. ;
Blackstone, Eugene H. ;
Grunkemeier, Gary L. ;
Takkenberg, Johanna J. M. ;
David, Tirone E. ;
Butchart, Eric G. ;
Adams, David H. ;
Shahian, David M. ;
Hagl, Siegfried ;
Mayer, John E. ;
Lytle, Bruce W. .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2008, 33 (04) :523-528
[2]   Impact of Bleeding on Quality of Life in Patients on DAPT Insights From TRANSLATE-ACS [J].
Amin, Amit P. ;
Wang, Tracy Y. ;
McCoy, Lisa ;
Bach, Richard G. ;
Effron, Mark B. ;
Peterson, Eric D. ;
Cohen, David J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (01) :59-65
[3]  
[Anonymous], 2016, IMTA DIS BURDEN CALC
[4]  
Arias E., 2004, NATL VITAL STAT REPO, V2007, P56
[5]   Factors determining utility measured with the EQ-5D in patients with atrial fibrillation [J].
Berg, Jenny ;
Lindgren, Peter ;
Nieuwlaat, Robby ;
Bouin, Olivier ;
Crijns, Harry .
QUALITY OF LIFE RESEARCH, 2010, 19 (03) :381-390
[6]   DEATH AND OTHER TIME-RELATED EVENTS AFTER VALVE-REPLACEMENT [J].
BLACKSTONE, EH ;
KIRKLIN, JW .
CIRCULATION, 1985, 72 (04) :753-767
[7]   Can We Grow Valves Inside the Heart? Perspective on Material-based In Situ Heart Valve Tissue Engineering [J].
Bouten, Carlijn V. C. ;
Smits, Anthal I. P. M. ;
Baaijens, Frank P. T. .
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2018, 5
[8]  
Briggs A., 2006, Decision modelling for health economic evaluation, DOI DOI 10.1016/J.EJOGRB.2017.03.029
[9]   THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS [J].
Buisman, Leander R. ;
Rutten-van Moelkn, Maureen P. M. H. ;
Postmus, Douwe ;
Luime, Jolanda J. ;
Uyl-de Groot, Carin A. ;
Redekop, William K. .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (1-2) :46-53
[10]   TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility [J].
Buyukkaramikli, Nasuh C. ;
Rutten-van Molken, Maureen P. M. H. ;
Severens, Johan L. ;
Al, Maiwenn .
PHARMACOECONOMICS, 2019, 37 (11) :1391-1408